Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma
Cancers · 23.05.2026 · 18 (11) · 1701
DOI: 10.3390/cancers18111701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.05.2026. Verfasst von Nguyen Tran Quang Sang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vinmec International Hospital.
Abstract (Originalsprache)
Background
Osteosarcoma remains the most common primary malignant bone tumor in children and adolescents, with largely unchanged survival outcomes in recent decades. Non-invasive biomarkers for preoperative risk stratification are urgently needed. Circulating immune checkpoint proteins (ICPs) and bone remodeling factors (BRFs) represent promising candidates; however, their combined prognostic value in osteosarcoma remains unclear.
Methods
We prospectively analyzed plasma samples from 47 patients with osteosarcoma, selecting the earliest available sample before disease progression or the last follow-up. A panel of ICPs and BRFs was quantified using multiplex immunoassays. sHVEM and sCD27 were used to construct a two-marker ICP signature (ICP2); subtypes were defined by unsupervised consensus clustering (k = 2) applied to log2-transformed sHVEM and sCD27 concentrations, and sOPN was included for integrative analysis. Survival associations were assessed using Kaplan–Meier analysis and Firth’s penalized Cox regression. The model performance was evaluated using Harrell’s C-index.
Results
Two ICP2 subtypes were identified (type1, n = 26; type2, n = 21). ICP2-type2 was associated with significantly worse progression free survival (PFS) (p = 0.0045) and overall survival (OS) (p = 0.0024) and remained an independent predictor after adjusting clinicopathological factors. The ICP2 model demonstrated high discriminative performance (C-index 0.924 for PFS and 0.903 for OS). Internal validation by leave-one-out cross-validation (LOOCV), in which consensus clustering was re-derived at each fold, yielded corrected C-indices of 0.612 for PFS and 0.806 for OS (versus apparent estimates of 0.687 and 0.689, respectively), confirming acceptable-to-good discrimination after accounting for overfitting. Elevated sOPN was associated with poorer survival in the exploratory analyses, although its prognostic value was less consistent under a pre-specified cutoff. In the combined models, sOPN provided modest additional value for OS stratification, with the grdgfdgICP2-type2/OPN-high subgroup exhibiting the poorest outcome.
Conclusions
The circulating sHVEM/sCD27 signature defines prognostically distinct osteosarcoma subtypes with a strong discriminative performance. This minimally invasive model may support preoperative risk stratification. Integration with sOPN suggests a potential biological link between immune regulation and bone remodeling, warranting validation in larger cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Global Education and Medical Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
- Orthopedic Trauma & Sports Medicine Center, Vinmec Times City International Hospital, Vinmec Healthcare System, Hanoi 100000, Vietnam.
- Department of Pathology, Vinmec Times City International Hospital, Vinmec Healthcare System, Hanoi 100000, Vietnam.
- Department of Orthopaedic Surgery, College of Health Science, VinUniversity, Hanoi 100000, Vietnam.
- Department of Anesthesia and Pain Management, Vinmec Times City International Hospital, Vinmec Healthcare System, Hanoi 100000, Vietnam.
- Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
ORCID-Profile: Tran Trung Dung, Tran Duc Thanh, Dang Minh Quang, Pham Tuan Anh, Tran Van Bao, Hidetomi Terai, Le Thi Thanh Thuy
Förderung
- Vinmec International Hospital
Zitieren
APA
Sang, N. T. Q., Khanh, N. V., Hai, H., Dung, T. T., Thanh, T. D., Quang, D. M., Anh, P. T., Chi, N. B. T., Bao, T. V., Trung, N. V., Hien, T. T. T., Terai, H., & Thuy, L. T. T. (2026). Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma. Cancers, 18(11), 1701. https://doi.org/10.3390/cancers18111701
Vancouver
Sang NTQ, Khanh NV, Hai H, Dung TT, Thanh TD, Quang DM, et al. Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma. Cancers. 2026;18(11):1701. doi:10.3390/cancers18111701
BibTeX
@article{Sang2026,
author = {Sang, Nguyen Tran Quang and Khanh, Nguyen Van and Hai, Hoang and Dung, Tran Trung and Thanh, Tran Duc and Quang, Dang Minh and Anh, Pham Tuan and Chi, Nguyen Bui Tam and Bao, Tran Van and Trung, Nguyen Viet and Hien, Tran Thi Thu and Terai, Hidetomi and Thuy, Le Thi Thanh},
title = {Integration of Circulating Immune Checkpoint Proteins and Osteopontin Refined Risk Stratification in Osteosarcoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {11},
pages = {1701},
doi = {10.3390/cancers18111701}
}
EUVIMED